Related references
Note: Only part of the references are listed.Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice
Haibo Li et al.
BIOMEDICAL CHROMATOGRAPHY (2011)
Synthesis and evaluation of compounds that induce readthrough of premature termination codons
Michael E. Jung et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis
Isabelle Sermet-Gaudelus et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Illuminating Insights into Firefly Luciferase and Other Bioluminescent Reporters Used in Chemical Biology
Natasha Thorne et al.
CHEMISTRY & BIOLOGY (2010)
Site-directed gene repair of the dystrophin gene mediated by PNA-ssODNs
Refik Kayali et al.
HUMAN MOLECULAR GENETICS (2010)
A 3 months mild functional test regime does not affect disease parameters in young mdx mice
Maaike van Putten et al.
NEUROMUSCULAR DISORDERS (2010)
Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124
Douglas S. Auld et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy
Vinod Malik et al.
Therapeutic Advances in Neurological Disorders (2010)
Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta
Sylvia A. Vetrone et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Nonaminoglycoside compounds induce readthrough of nonsense mutations
Liutao Du et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
PRECLINICAL DRUG TRIALS IN THE mdx MOUSE: ASSESSMENT OF RELIABLE AND SENSITIVE OUTCOME MEASURES
Christopher F. Spurney et al.
MUSCLE & NERVE (2009)
Nonsense suppression activity of PTC124 (ataluren)
Stuart W. Peltz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression
Douglas S. Auld et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy
Jachinta E. Rooney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry
Etsuko Watanabe et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice
Haifang Yin et al.
MOLECULAR THERAPY (2008)
Messenger RNA surveillance systems monitoring proper translation termination
Nobuyoshi Akimitsu
JOURNAL OF BIOCHEMISTRY (2008)
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch et al.
NATURE (2007)
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers
Samit Hirawat et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology
J Alter et al.
NATURE MEDICINE (2006)
Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration
C Bertoni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Early nonsense: mRNA decay solves a translational problem
Nadia Amrani et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Strand bias in oligonucleotide-mediated dystrophin gene editing
C Bertoni et al.
HUMAN MOLECULAR GENETICS (2005)
Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons
CH Lai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations
M Wilschanski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping
C Bertoni et al.
HUMAN MOLECULAR GENETICS (2003)
Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene
M Du et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2002)
Dystrophin gene repair in mdx muscle precursor cells in vitro and in vivo mediated by RNA-DNA chimeric oligonucleotides
C Bertoni et al.
HUMAN GENE THERAPY (2002)
Effect of blood collection technique in mice on clinical pathology parameters
MA Schnell et al.
HUMAN GENE THERAPY (2002)
Three mouse models of muscular dystrophy:: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin α2-deficient mice
AM Connolly et al.
NEUROMUSCULAR DISORDERS (2001)
Diagnosis of Duchenne dystrophy by enhanced detection of small mutations
JR Mendell et al.
NEUROLOGY (2001)
Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of α-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation
KM Keeling et al.
HUMAN MOLECULAR GENETICS (2001)
Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy
A Ahmad et al.
HUMAN MOLECULAR GENETICS (2000)
Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system
M Manuvakhova et al.
RNA (2000)
Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice
JA Rafael et al.
MAMMALIAN GENOME (2000)